Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Josephine Mauskopf, Sandra Talbird & Baudouin Standaert. (2012) Categorization of methods used in cost–effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models. Expert Review of Pharmacoeconomics & Outcomes Research 12:3, pages 357-371.
Read now
Read now
Articles from other publishers (19)
Mireia Diaz, Silvia de Sanjosé, F. Xavier Bosch & Laia Bruni. (2018) Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses. Reports of Practical Oncology & Radiotherapy 23:6, pages 484-494.
Crossref
Crossref
Siok Shen Ng, Raymond Hutubessy & Nathorn Chaiyakunapruk. (2018) Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination. Vaccine 36:19, pages 2529-2544.
Crossref
Crossref
Michael Herdman, Amanda Cole, Christopher K. Hoyle, Victoria Coles, Stuart Carroll & Nancy Devlin. (2016) Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review. Value in Health 19:2, pages 255-266.
Crossref
Crossref
F. Xavier Bosch, Claudia Robles, Mireia Díaz, Marc Arbyn, Iacopo Baussano, Christine Clavel, Guglielmo Ronco, Joakim Dillner, Matti Lehtinen, Karl-Ulrich Petry, Mario Poljak, Susanne K. Kjaer, Chris J. L. M. Meijer, Suzanne M. Garland, Jorge Salmerón, Xavier Castellsagué, Laia Bruni, Silvia de Sanjosé & Jack Cuzick. (2015) HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nature Reviews Clinical Oncology 13:2, pages 119-132.
Crossref
Crossref
José Ramón Estela Cubells. (2015) Impacto de la vacunación en la incidencia de condilomas acuminados. Piel 30:4, pages 209-210.
Crossref
Crossref
Leonardo Simonella & Karen Canfell. (2015) Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries. Vaccine 33:1, pages 34-51.
Crossref
Crossref
Paul L. McCormack. (2014) Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): A Review of Its Use in the Prevention of Premalignant Anogenital Lesions, Cervical and Anal Cancers, and Genital Warts. Drugs 74:11, pages 1253-1283.
Crossref
Crossref
Lianne Barnieh, Fiona Clement, Anthony Harris, Marja Blom, Cam Donaldson, Scott Klarenbach, Don Husereau, Diane Lorenzetti & Braden Manns. (2014) A Systematic Review of Cost-Sharing Strategies Used within Publicly-Funded Drug Plans in Member Countries of the Organisation for Economic Co-Operation and Development. PLoS ONE 9:3, pages e90434.
Crossref
Crossref
Anneli Uusküla, Andres Müürsepp, Kosuke Kawai, Mait Raag, Mikk Jürisson & Matthew Pillsbury. (2013) The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia. BMC Infectious Diseases 13:1.
Crossref
Crossref
Johannes Berkhof, Johannes A. Bogaards, Erhan Demirel, Mireia Diaz, Monisha Sharma & Jane J. Kim. (2013) Cost-Effectiveness of Cervical Cancer Prevention in Central and Eastern Europe and Central Asia. Vaccine 31, pages H71-H79.
Crossref
Crossref
Gary M. Ginsberg. (2013) Cost-Utility Analysis of Interventions to Reduce the Burden of Cervical Cancer in Israel. Vaccine 31, pages I46-I52.
Crossref
Crossref
Zoltán Vokó, László Nagyjánosi & Zoltán Kaló. (2012) Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary. BMC Public Health 12:1.
Crossref
Crossref
Karen Canfell, Harrell Chesson, Shalini L. Kulasingam, Johannes Berkhof, Mireia Diaz & Jane J. Kim. (2012) Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries. Vaccine 30, pages F157-F167.
Crossref
Crossref
Chun-Fu Tai, Tsung-Pei Tsou, Wu-Shiun Hsieh, Chien-Yi Chen, Hung-Chieh Chou, Po-Nien Tsao, Chien-hui Hsu, Yi-Jen Liau, Chun-Yi Lu, Pei-Lan Shao, Luan-Yin Chang & Li-Min Huang. (2012) Molecular detection and incidence of human papillomavirus in neonates: Methodology and a pilot study in a medical center. Journal of Microbiology, Immunology and Infection 45:3, pages 185-192.
Crossref
Crossref
Katherine Seto, Fawziah Marra, Adam Raymakers & Carlo A. Marra. (2012) The Cost Effectiveness of Human Papillomavirus Vaccines. Drugs 72:5, pages 715-743.
Crossref
Crossref
Adam J.N. Raymakers, Mohsen Sadatsafavi, Fawziah Marra & Carlo A. Marra. (2012) Economic and Humanistic Burden of External Genital Warts. PharmacoEconomics 30:1, pages 1-16.
Crossref
Crossref
Paul L. McCormack & Elmar A. Joura. (2011) Spotlight on Quadrivalent Human Papillomavirus(Types 6, 11, 16, 18) Recombinant Vaccine(Gardasil®) in the Prevention of PremalignantGenital Lesions, Genital Cancer, and Genital Warts in Women†. BioDrugs 25:5, pages 339-343.
Crossref
Crossref
Paul L. McCormack & Elmar A. Joura. (2010) Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®). Drugs 70:18, pages 2449-2474.
Crossref
Crossref
Philippe Beutels & Mark Jit. (2010) A brief history of economic evaluation for human papillomavirus vaccination policy. Sexual Health 7:3, pages 352.
Crossref
Crossref